The Phase 1 data are encouraging but early-stage; the key catalyst is the Phase 3 PRISM-MEL-301 trial readout. Monitor for enrollment updates and interim data. The stock may see modest positive movement on ASCO presentation buzz, but sustained upside depends on Phase 3 results.
IMCR drugs
IMCR drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 1 $29.13entry
- T+1 · 6mo ago +1.48%α +1.33% · $29.56
- T+5 · 5mo ago −2.88%α −0.13% · $28.29
- T+20 · 5mo ago +8.99%α +10.29% · $31.75
- T+60 · 3mo ago +28.39%α +27.16% · $37.40
Price Chart
How similar events traded
Executive Summary
Immunocore presented updated Phase 1 data for brenetafusp in heavily pretreated advanced melanoma at ASCO 2026, showing a 6-month OS rate of 87% and DCR of 52% in 66 patients. The data support the 160 mcg dose selection for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma. While the results are clinically promising, the small sample size and early-stage nature limit immediate stock-moving impact.
Key Facts
- Brenetafusp monotherapy in 66 heavily pretreated advanced melanoma patients showed 6-month OS rate of 87% and median OS of 14.3 months.
- Disease control rate (DCR) was 52% and overall response rate (ORR) was 12%.
- Data support 160 mcg dose selection for Phase 3 PRISM-MEL-301 trial (brenetafusp + nivolumab vs. standard nivolumab regimens) in first-line advanced melanoma.
- Clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance (median OS 14.7 months).
- Brenetafusp was generally well tolerated; most common TRAEs were CRS (56%), rash (44%), pyrexia (44%), and chills (38%), predominantly low grade.
- A second poster showed IL7 may enhance ImmTAC anti-tumor activity in vitro and in vivo.
Financial Impact
No financial data provided; early-stage clinical data with no revenue or guidance impact.
Risk Factors
- Phase 3 trial may fail to replicate Phase 1 efficacy in a larger, randomized setting.
- Competition from existing PD-1/CTLA-4 and LAG-3 therapies in first-line melanoma.
- Safety profile includes CRS and lymphopenia, which could limit tolerability in broader patient populations.
- Small sample size (n=66) limits statistical reliability of efficacy estimates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303917 |
Track record
14 reports on IMCR
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 9, 20267d ago SC 13G Neutral 4/10 Entry $32.38 Now $28.88 −10.81% settles Feb 8
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $30.99 Now $28.88 −6.81% settles Feb 4
- Nov 6, 202610d ago 8-K Neutral 4/10 No price data
- Nov 6, 202610d ago Press Release Bearish 5/10 Entry $30.99 Now $28.88 +6.81% settles Feb 4
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $31.27 Now $28.88 −7.64% settles Jan 27
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $29.48 Now $28.88 −2.04% settles Jan 12
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $29.41 Now $28.88 −1.80% settles Jan 4
- Sep 14, 20269w ago 8-K Bullish 6/10 Entry $32.46 Now $28.88 −11.03% settles Dec 8
- Aug 6, 202614w ago 8-K Mixed 5/10 Entry $34.50 to $30.49 Now $28.88 −16.29% ▼ −11.62% −9.95% vs SPY
- May 31, 202624w ago Press Release Bullish 6/10 Viewing Entry $29.13 to $37.40 Now $28.88 −0.86% ▲ +28.39% +27.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers